Tahir Latif , MBBS,MBA

Dr. Latif is actively involved in clinical research and scholarly activities in hematologic malignancies and GI oncology, having published numerous peer-reviewed journal articles, as well as review articles in prestigious journals such as Bone Marrow Transplantation, Critical Review in Hematology Oncology, and Experimental Hematology.  

Dr. Latif currently serves as Professor of Clinical Medicine in the Division of Hematology Oncology and Director of Infusion Services, UCMC, is a practicing Hematologist and Oncologist with special interest in malignant hematology (lymphoproliferative disorders). Dr. Latif graduated from Allama Iqbal Medical College, University of the Punjab in 1996 and completed his residency and fellowship training from Cleveland Clinic Florida and Cleveland Clinic foundation respectively. He’s been in practice for over 15 years and has trained and educated many oncologists in Cincinnati Area. 

He has keen interest in improving efficiency and quality of health care with development of lean systems and has adopted several process improvement initiative at Univercity of Cincinnati since his arrival. 

Bachelor's Degree: Punjab University 1993 (Science )

Medical Degree: Allama Iqbal Medical College 1996 (Medicine and Surgery )

Internship: Cleveland Clinic Florida Ft. Lauderdale, FL, 1999 (Internal Medicine)

Residency: Cleveland Clinic Florida Ft. Lauderdale, FL, 2001 (Internal Medicine)

Fellowship: Cleveland Clinic Foundation Cleveland, Ohio, 2004 (Hematology and Medical Oncology)

Master's Degree: Texas Tech University Rawls College of Business Administration 2009 (Business )

American Board of Internal Medicine (Hematology) (Certification Date: 11-03-2004 ) - (Recertification Date: to 07-16-2024 )

American Board of Internal Medicine (Medical Oncology) (Certification Date: 11-03-2004 ) - (Recertification Date: to 07-16-2024 )

Hematology and Oncology

Leukemia

Medical Oncology

Acute Lymphocytic Leukemia

Acute Myeloid Leukemia

Amyloidosis

Anal Cancer

Castleman Disease

Chronic Lymphocytic Leukemia

Chronic Myelogenous Leukemia

Colon Cancer

Lymphadenopathy

Lymphoma

M Protein

Macrocytosis

Macroglobulinemia

Mantle Cell Lymphoma

Mediastinal Adenopathy

Monoclonal gammopathy

Monoclonal protein

M-Spike

Mycosis Fugoides

Myelodysplastic Syndrome

Myeloma

Myeloproliferative Disorder

Paraproteinemia

Plasma Cell Disorder

Plasminogen Activator Inhibitor 1

Polycythemia vera

Proteinuria

Rectal Cancer

Sideroblastic anemia

T-cell lymphoma

Hematology

Internal Medicine

Medical Oncology

Hematological Cancers, Colorectal Cancer  

07-2004 -04-2010 Hematologist, Medical Oncologist, Kymera Independent Physicians, Cancer Treatment Center, Carlsbad, NM

2008 -2010 Clinical Assistant Professor, Department of Internal Medicine, The University of New Mexico, School of Medicine, ABQ, NM

2007 -2010 Adjunct Assistant Professor, Department of Medicine, Division of Hematology and Medical Oncology , Lubbock, TX

09-2013 -08-2017 Associate Professor Clinical Medicine, University of Cincinnati,

05-2010 -08-2013 Assistant Professor Clinical Medicine, University of Cincinnati,

Investigators:Latif, Tahir 01-31-2022 -01-30-2025 MorphoSys AG A phase 3, multicenter, RDBPCT comparing efficacy & safety of tafasitamab plus lenalidomide in addition to R-CHOP ves R-CHOP in previously untreated highintermediate and high-risk patients with DLBCL Role:PI 0.00 Hold Level:Industry

Grant: #MOR208C310 Investigators:Latif, Tahir 02-01-2022 -01-31-2025 MorphoSys AG A phase 3, multicenter, RDBPCT comparing efficacy & safety of tafasitamab plus lenalidomide in addition to R-CHOP ves R-CHOP in previously untreated highintermediate and high-risk patients with DLBCL Role:PI 529272.80 Hold Level:Industry

Grant: #MK2140-004 10-01-2021 -09-30-2024 Merck Sharp & Dohme Corp A Phase 2 Open-label Clinical Study to Evaluate the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Role:PI 780542.85 Hold Level:Industry

Grant: #MK2140-004 10-01-2021 -09-30-2024 Merck Sharp & Dohme Corp A Phase 2 Open-label Clinical Study to Evaluate the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Role:PI 780542.85 Hold Level:Industry

Grant: #CNTY-101-111-01 01-03-2023 -01-03-2027 IQVIA Biotech The ELiPSE study: A Phase 1, Multicenter, Open-Label Study of CNTY-101 in Subjects with Relapsed or Refractory CD19-Positive B-Cell Malignancies Role:PI 0.00 Active Level:Industry

Grant: #CNTY-101-111-01 01-03-2023 -01-03-2027 IQVIA Biotech The ELiPSE study: A Phase 1, Multicenter, Open-Label Study of CNTY-101 in Subjects with Relapsed or Refractory CD19-Positive B-Cell Malignancies Role:PI 0.00 Active Level:Industry

Grant: #ALLO-647-201 Investigators:Latif, Tahir 06-06-2023 -06-06-2026 Allogene Therapeutics Inc. A STUDY EVALUATING LYMPHODEPLETION WITH FLUDARABINE, CYCLOPHOSPHAMIDE, AND ALLO-647, VS. FLUDARABINE AND CYCLOPHOSPHAMIDE ALONE, IN SUBJECTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (LBCL) Role:PI 986744.20 Hold Level:Industry

Grant: #MPCT-012L Investigators:Latif, Tahir 08-18-2023 -08-18-2026 Immpact Bio USA INC. MPCT-012L A PHASE 1/2 MULTI-CENTER STUDY EVALUATING THE SAFETY ANDEFFICACY OF IMPT-314, Role:PI 1095324.00 Hold Level:Industry

Grant: #M20-621 Investigators:Latif, Tahir 09-21-2023 -09-21-2026 AbbVie, Inc. A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP Compared to R-CHOP in Subjects with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLB Role:PI 776596.46 Hold Level:Industry

Grant: #CNTY-101-111-01 01-03-2023 -01-03-2027 IQVIA Biotech The ELiPSE study: A Phase 1, Multicenter, Open-Label Study of CNTY-101 in Subjects with Relapsed or Refractory CD19-Positive B-Cell Malignancies Role:PI 0.00 Active Level:Industry

Grant: #CNTY-101-111-01 01-03-2023 -01-03-2027 IQVIA Biotech The ELiPSE study: A Phase 1, Multicenter, Open-Label Study of CNTY-101 in Subjects with Relapsed or Refractory CD19-Positive B-Cell Malignancies Role:PI 0.00 Active Level:Industry

Grant: #CNTY-LTFU-01 Investigators:Latif, Tahir 12-20-2023 -12-20-2026 Century Therapeutics, Inc. A Long-Term Follow-up Study for Subjects Previously Treated with A Century Therapeutics Cellular Therapy Product Role:PI 183062.00 Hold Level:Industry

Grant: #ALLO-501A-202 Investigators:Latif, Tahir 09-05-2024 -09-05-2027 Allogene Therapeutics Inc. A RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FOR LARGE B-CELL LYM Role:PI 490617.83 Hold Level:Industry

Published Abstracts

J. Shah, T. Latif, P. Elson, E. Hsi, M. Kalaycio (2005. ) A retrospective study comparing demographics, cytogentic findings, and prognosis in acute myeloid leukemia with and without leukemia cutis .[Abstract]Proc Am Soc Clin Oncol , 23 ,

T. S. Chan, T. Latif, B. Pohlman, K. Theil, P. Elson, R. Sobecks, B. Bolwell, M. Kalaycio (2004. ) High dose therapy (HDT) and autologous stem cell transplantation (ASCT) in diffuse large B cell lymphoma (DLBL) patients with secondary central nervous system (CNS) involvement .[Abstract]Journal of Clinical Oncology, ASCO Annual Meeting Proceedings (Post Meeting Edition) , 22 (14S-July 15 Supplement ) ,6658

Latif T, Kalaycio M, Pohlman B, Sobecks R, Andresen S, Rybicki L, Kuczkowski E, Cherni K, Bernhard L, Ostendorf H, Bolwell B (2003. ) The prognostic significance of the day 12 and day 42 platelet count after autologous stem cell transplant (ASCT) in patients with diffuse large B cell lymphoma (DLBL) .[Abstract]Blood 2003, 102 (11 ) ,[2722]

Latif T, Elson P, Karam MA, Reed J, Tahir K, Srkalovic G, Hussein MA (2003. ) Incidence of renal impairment (RI) in Multiple Myeloma (MM) patients receiving combination chemotherapy and thalidomide (Thal) with bisphosphonate therapy .[Abstract]Blood 2003, 102 (11 ) ,[2545]

Wlodarski M, Wu R, Magdalena P, Latif T, Lichtin A, Maciejewski JP (2003. ) Can seldi mass spectrometry serum proteomics be applied to improve diagnosis of ITP? .[Abstract]Blood 2003, 102 (11 ) ,[1049]

Latif T, Bolwell B, Rybicki L, Kuczkowski E, Kalaycio M, Jarvis J, Sobecks R, Andresen Pohlman B, Maciejewski J (2003. ) Analysis of CD34 subsets of patients undergoing autologous stem cell transplant (ABMT) with cells mobilized by either G-CSF alone or G-CSF plus VP 16 .[Abstract]Blood 2003, 102 (11 ) ,8b [3571]

Latif T, Kalaycio M, Pohlman B, Sobecks R, Andresen S, Rybicki L, Brown S, Kuczkowski E, Bernhard L, Ostendorf H, Cherni K, Bolwell B The prognostic significance of the absolute lymphocyte count (ALC) at day 12 and day 42 after autologous stem cell transplant (ASCT) in patients with diffuse large B cell lymphoma (DLBL) .[Abstract]Blood 2003, 102 (11 ) ,[5444]

Latif T, Elson P, Karam MA, Reed J, Tso E, Srkalovic G, Hussein MA Liposomal doxorubicin, Vincristine, reduced frequency Dexamethsone and Thalidomide (DVd-T) for newly diagnosed Multiple Myeloma (MM) patients .[Abstract]Proc Am Soc Clin Oncol 2003, 11 ,601a (A 2419)

Latif T, Hsi E, Rybicki L, Adelstein D Efficacy of serum folate determination in clinical practice .[Abstract]Blood 2002, 100 (11 ) ,8b [3482]

Latif T, Skelton J, Perez-Tripichio A, Woodhouse, S (2000. ) A lot of normal folate levels! .[Abstract]Proceedings of ACP-ASIM Florida Chapter Annual Meeting 2000,

Latif T, Steiman D, Gourgouh P Massive right atrial thrombus due to hickman catheter requiring open-heart surgery .[Abstract]Proceedings of ACP-ASIM Florida Chapter annual meeting 1999,

Aziz Z, Qazi S, Latif T, Akram S, Rehman A Prevalence of anxiety and depression in cancer patients receiving chemotherapy .[Abstract]Annals of Oncology 1998, 11 (4 ) ,143

Peer Reviewed Publications

Ghose, Abhimanyu; Kundu, Ria; Latif, Tahir (2014. ) Prophylactic CNS directed therapy in systemic diffuse large B cell lymphoma.Critical reviews in oncology/hematology, , More Information

Haider, S; Latif, T; Hochhausler, A; Lucas, F; Abdel Karim, N (2013. ) Waldenstrom's Macroglobulinemia and Peripheral Neuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes with a Bleeding Diathesis and Rash.Case reports in oncological medicine, , 2013 ,890864 More Information

Latif, Tahir; Chauhan, Nabeel; Khan, Rashid; Moran, Andrea; Usmani, Saad Z (2012. ) Thalidomide and its analogues in the treatment of Multiple Myeloma.Experimental hematology & oncology, , 1 (1 ) ,27 More Information

Raza, Azra; Cruz, Raymond; Latif, Tahir; Mukherjee, Siddhartha; Galili, Naomi (2010. ) The biology of myelodysplastic syndromes: unity despite heterogeneity.Hematology reports, , 2 (1 ) ,e4 More Information

Latif, Tahir; Hussein, Mohamad A (2005. ) Advances in multiple myeloma and spine disease.Clinical lymphoma & myeloma, , 6 (3 ) ,228-33 More Information

Latif, Tahir; Wood, Laura; Connell, Cindy; Smith, David C; Vaughn, David; Lebwohl, David; Peereboom, David (2005. ) Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC).Investigational new drugs, , 23 (1 ) ,79-84 More Information

Latif, T; Hsi, E D; Rybicki, L A; Adelstein, D J (2004. ) Is there a role for folate determinations in current clinical practice in the USA?.Clinical and laboratory haematology, , 26 (6 ) ,379-83 More Information

Latif, T; Pohlman, B; Kalaycio, M; Sobecks, R; Hsi, E D; Andresen, S; Bolwell, B J (2003. ) Syngeneic graft-versus-host disease: a report of two cases and literature review.Bone marrow transplantation, , 32 (5 ) ,535-9 More Information

Latif, T; Steiman, D M; Gagaoudakis, P (2001. ) Massive right atrial thrombosis due to Hickman catheter requiring open heart surgery--a case report. Angiology, , 52 (6 ) ,425-8

Jagannathan, S; Abdel-Malek, M A Y; Malek, E; Vad, N; Latif, T; Anderson, K C; Driscoll, J J (2015. ) Pharmacologic screens reveal metformin that suppresses GRP78-dependent autophagy to enhance the anti-myeloma effect of bortezomib.Leukemia, , 29 (11 ) ,2184-91 More Information

Ghose, Abhimanyu; Elias, Harold Kunal; Guha, Gunjan; Yellu, Mahender; Kundu, Ria; Latif, Tahir (2015. ) Influence of Rituximab on Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma and Role of Prophylaxis--A Systematic Review of Prospective Studies.Clinical lymphoma, myeloma & leukemia, , 15 (8 ) ,451-7 More Information

Blanco, Victor M; Latif, Tahir; Chu, Zhengtao; Qi, Xiaoyang (2015. ) Imaging and Therapy of Pancreatic Cancer with Phosphatidylserine-Targeted Nanovesicles.Translational oncology, , 8 (3 ) ,196-203 More Information

Ghose, Abhimanyu; Yellu, Mahender; Wise-Draper, Trisha; Sharma, Divya; Qualtieri, Julianne; Latif, Tahir; Medlin, Stephen (2014. ) Lymphoma presenting as secondary HLH: a review with a tale of two cases.Clinical lymphoma, myeloma & leukemia, , 14 (6 ) ,e187-93 More Information

Kharofa, Jordan; Mierzwa, Michelle; Olowokure, Olugbenga; Sussman, Jeffrey; Latif, Tahir; Gupta, Anumeha; Xie, Changchun; Patel, Sameer; Esslinger, Hope; Mcgill, Brian; Wolf, Eric; Ahmad, Syed A (2019. ) Pattern of Marginal Local Failure in a Phase II Trial of Neoadjuvant Chemotherapy and Stereotactic Body Radiation Therapy for Resectable and Borderline Resectable Pancreas Cancer.American journal of clinical oncology, , 42 (3 ) ,247-252 More Information

Das, M K; Ali, M A; Latif, T; Islam, M N; Hossain, M A; Moniruzzaman, M M; Oliullah, M; Haque, S A; Gosh, A K (2018. ) Comparison of Serum Electrolytes Abnormality and Renal Function Status in Asphyxiated and Normal Baby in a Tertiary Level Hospital. Mymensingh medical journal : MMJ, , 27 (4 ) ,723-729

Kim, Young; Stahl, Christopher C; Makramalla, Abouelmagd; Olowokure, Olugbenga O; Ristagno, Ross L; Dhar, Vikrom K; Schoech, Michael R; Chadalavada, Seetharam; Latif, Tahir; Kharofa, Jordan; Bari, Khurram; Shah, Shimul A (2017. ) Downstaging therapy followed by liver transplantation for hepatocellular carcinoma beyond Milan criteria.Surgery, , 162 (6 ) ,1250-1258 More Information

Book Chapter

Latif T, Morris JC (2013 ) Antibody therapy for T Cell lymphoma T-Cell Leukemia - Characteristics, Treatment and Prevention .

Poster Presentations

T. S. Chan, T. Latif, B. Pohlman, K. Theil, P. Elson, R. Sobecks, B. Bolwell, M. Kalaycio (2004. ) High dose therapy (HDT) and autologous stem cell transplantation (ASCT) in diffuse large B cell lymphoma (DLBL) patients with secondary central nervous system (CNS) involvement. (Accepted for Poster Presentation) .ASCO , Professional Meeting. .

Latif T, Kalaycio M, Pohlman B, Sobecks R, Andresen S, Rybicki L, Kuczkowski E, Cherni K, Bernhard L, Ostendorf H, Bolwell B (2003. ) The prognostic significance of the day 12 and day 42 platelet count after autologous stem cell transplant (ASCT) in patients with diffuse large B cell lymphoma (DLBL). .ASH , Professional Meeting. .

Latif T, Elson P, Karam MA, Reed J, Tahir K, Srkalovic G, Hussein MA (2003. ) Incidence of renal impairment (RI) in Multiple Myeloma (MM) patients receiving combination chemotherapy and thalidomide (Thal) with bisphosphonate therapy. .ASH, Professional Meeting. .

Latif T, Bolwell B, Rybicki L, Kuczkowski E, Kalaycio M, Jarvis J, Sobecks R, Andresen Pohlman B, Maciejewski J (2003. ) Analysis of CD34 subsets of patients undergoing autologous stem cell transplant (ABMT) with cells mobilized by either G-CSF alone or G-CSF plus VP 16. .ASH, Professional Meeting. .

Wlodarski M, Wu R, Magdalena P, Latif T, Lichtin A, Maciejewski JP (2003. ) Can SELDI mass spectrometry serum proteomics be applied to improve diagnosis of ITP? .ASH, Professional Meeting. .

Latif T, Elson P, Karam MA, Reed J, Tso E, Srkalovic G, Hussein MA (2003. ) Liposomal doxorubicin, Vincristine, reduced frequency Dexamethsone and Thalidomide (DVd-T) for newly diagnosed Multiple Myeloma (MM) patients. .ASCO, Professional Meeting. .

Latif T, Steiman D, Gourgouh P (1999. ) Massive right atrial thrombus due to hickman catheter requiring open heart surgery. ACP ASIM Florida Chapter Annual Meeting,

Aziz Z, Qazi S, Latif T, Akram S, Rehman A (1998. ) Prevalence of anxiety and depression in cancer patients receiving chemotherapy. 23rd Congress of ESMO,

Lecture

Latif, Tahir (07-2007. ) Myelodysplatic Syndrome: Why Should an Internist Care? .University of Cincinnati.

Latif, T (07-2007. ) Myelodysplatic Syndrome .University of Cincinnati.

Latif, T (09-2009. ) Lung Cancer - What will I change after ASCO 2009: A Community Oncologist's perspective .University of Rochester.

Latif, T (01-2009. ) Management of Vitamin K antagonists, ACP guidelines .Carlsbad Medical Center.

Latif, T (01-2009. ) Antithrombotic Therapy for Venous Thromboembolic Disease .Carlsbad Medical Center.

Latif, T (2007. ) Colon Cancer Screening for internists .Carlsbad Medical Center.

Latif, T (2006. ) Neutopenic Fever .Carlsbad Medical Center.

(2004. ) The prognostic significance of the day 12 and six weeks platelet count after autologous stem cell transplant (ASCT) in diffuse large B cell lymphoma (DLBL) patients .

Latif, T (2004. ) The prognostic significance of the day 12 and six weeks platelet count after autologous stem cell transplant (ASCT) in diffuse large B cell lymphoma (DLBL) patients .Galaxo-Smithkline Fellow’s Forum .

(2000. ) A lot of normal Folate levels! .

September 2007 - Smartest Oncologist in America (One of Top 50)

15th Annual Mayo Clinic Fellow's Travel Award

2003 -2004 AMGEM Research Fellow

2000 Jeffery B Sheroky Research Award; Cleveland Clinic Florida, Fort Lauderdale, FL

2000 Outstanding Presenter; Annual Associates Meeting, ACP-ASIM Florida Chapter

1991 -1996 Merit Scholarship; Federal Employee's Children Fund, Lahore, Pakistan

1996 College Color

1995 Editor (Scientific Section) & Secretary: SHAHEEN MAGAZINE, Allama Iqbal Medical College, Lahore, Pakistan

1994 Chairman, Drug Section; Patients Welfare Society (PWS); Allama Iqbal Medical College, Lahore, Pakistan

Hematology/Oncology, Cancer, Oncology, Head & Neck Cancer, Colorectal Cancer, Leukemia, Lung Cancer, Lymphoma

American Board of Internal Medicine

American Board of Medical Oncology,

American Board of Hematology,

Pakistan Medical and Dental Council,

American College of Physicians,

American Society of Clinical Oncology,

Association of Physicians of Pakistani Descent of North America,

Bioethics Committee, Carlsbad Medical Center,

Medication Usage/Infection Control Committee, Carlsbad Medical Center ,

Transfusion Review Committee, The Cleveland Clinic Foundation,

ACP - ASIM, New Mexico Chapter,

2008 - Secretary; 2009 - President Elect; 2010 - President; Allama Iqubal Medical Colelge Alumni Association of North America (AIMCAANA),

Academic - Vontz Center for Molecular Studies
3125 Eden Avenue
Cincinnati  Ohio, 45267
Phone: 513-558-2115
Fax: 513-558-2124
tahir.latif@uc.edu